169 related articles for article (PubMed ID: 11508393)
1. Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.
Simmons M; Murphy GS; Hayes CG
Am J Trop Med Hyg; 2001 Aug; 65(2):159-61. PubMed ID: 11508393
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice.
Simmons M; Nelson WM; Wu SJ; Hayes CG
Am J Trop Med Hyg; 1998 May; 58(5):655-62. PubMed ID: 9598457
[TBL] [Abstract][Full Text] [Related]
3. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
4. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine.
Simmons M; Murphy GS; Kochel T; Raviprakash K; Hayes CG
Am J Trop Med Hyg; 2001 Nov; 65(5):420-6. PubMed ID: 11716093
[TBL] [Abstract][Full Text] [Related]
5. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
Blaney JE; Matro JM; Murphy BR; Whitehead SS
J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
[TBL] [Abstract][Full Text] [Related]
6. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein.
Mota J; Acosta M; Argotte R; Figueroa R; Méndez A; Ramos C
Vaccine; 2005 May; 23(26):3469-76. PubMed ID: 15837370
[TBL] [Abstract][Full Text] [Related]
7. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
8. Evaluation in Mice of the Immunogenicity of a Tetravalent Subunit Vaccine Candidate Against Dengue Virus Using Mucosal and Parenteral Immunization Routes.
Lazo Vázquez L; Gil González L; Marcos López E; Pérez Fuentes Y; Cervetto de Armas L; Brown Richards E; Valdés Prado I; Suzarte Portal E; Cobas Acosta K; Yaugel Novoa M; Romero Fernández Y; Guillén Nieto G; Hermida Cruz L
Viral Immunol; 2017 Jun; 30(5):350-358. PubMed ID: 28418786
[TBL] [Abstract][Full Text] [Related]
9. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice.
Konishi E; Kosugi S; Imoto J
Vaccine; 2006 Mar; 24(12):2200-7. PubMed ID: 16316713
[TBL] [Abstract][Full Text] [Related]
10. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.
Clements DE; Coller BA; Lieberman MM; Ogata S; Wang G; Harada KE; Putnak JR; Ivy JM; McDonell M; Bignami GS; Peters ID; Leung J; Weeks-Levy C; Nakano ET; Humphreys T
Vaccine; 2010 Mar; 28(15):2705-15. PubMed ID: 20097152
[TBL] [Abstract][Full Text] [Related]
11. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.
Liu G; Song L; Beasley DW; Putnak R; Parent J; Misczak J; Li H; Reiserova L; Liu X; Tian H; Liu W; Labonte D; Duan L; Kim Y; Travalent L; Wigington D; Weaver B; Tussey L
Clin Vaccine Immunol; 2015 May; 22(5):516-25. PubMed ID: 25761459
[TBL] [Abstract][Full Text] [Related]
13. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice.
Zhang ZS; Yan YS; Weng YW; Huang HL; Li SQ; He S; Zhang JM
J Virol Methods; 2007 Aug; 143(2):125-31. PubMed ID: 17532481
[TBL] [Abstract][Full Text] [Related]
14. Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.
Izquierdo A; Valdés I; Gil L; Hermida L; Gutiérrez S; García A; Bernardo L; Pavón A; Guillén G; Guzmán MG
Antiviral Res; 2012 Jul; 95(1):1-8. PubMed ID: 22554934
[TBL] [Abstract][Full Text] [Related]
15. Differential dengue cross-reactive and neutralizing antibody responses in BALB/c and Swiss albino mice induced by immunization with flaviviral vaccines and by infection with homotypic dengue-2 virus strains.
Lim CS; Chua JJ; Wilkerson J; Chow VT
Viral Immunol; 2006; 19(1):33-41. PubMed ID: 16553548
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
Metz SW; Thomas A; Brackbill A; Xianwen Y; Stone M; Horvath K; Miley MJ; Luft C; DeSimone JM; Tian S; de Silva AM
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006793. PubMed ID: 30248097
[TBL] [Abstract][Full Text] [Related]
17. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model.
Chambers TJ; Liang Y; Droll DA; Schlesinger JJ; Davidson AD; Wright PJ; Jiang X
J Virol; 2003 Mar; 77(6):3655-68. PubMed ID: 12610141
[TBL] [Abstract][Full Text] [Related]
18. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.
Apt D; Raviprakash K; Brinkman A; Semyonov A; Yang S; Skinner C; Diehl L; Lyons R; Porter K; Punnonen J
Vaccine; 2006 Jan; 24(3):335-44. PubMed ID: 16125280
[TBL] [Abstract][Full Text] [Related]
19. Size-dependent neutralizing activity of gold nanoparticle-based subunit vaccine against dengue virus.
Quach QH; Ang SK; Chu JJ; Kah JCY
Acta Biomater; 2018 Sep; 78():224-235. PubMed ID: 30099200
[TBL] [Abstract][Full Text] [Related]
20. A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice.
Izquierdo A; García A; Lazo L; Gil L; Marcos E; Alvarez M; Valdés I; Hermida L; Guillén G; Guzmán MG
Arch Virol; 2014 Oct; 159(10):2597-604. PubMed ID: 24841761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
